RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and KITE PHARMA, INC. Dated as of December 31, 2014Research Collaboration and License Agreement • August 8th, 2016 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledAugust 8th, 2016 Company Industry JurisdictionThis RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 31, 2014 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 (“Kite”). Kite and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RESEARCH COLLABORATION AND LICENSE AGREEMENT by and between AMGEN INC. and KITE PHARMA, INC. Dated as of December 31, 2014Research Collaboration and License Agreement • March 26th, 2015 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 26th, 2015 Company Industry JurisdictionThis RESEARCH COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 31, 2014 (the “Signing Date”) by and between AMGEN INC., a Delaware corporation having an address at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”), and KITE PHARMA, INC., a Delaware corporation having an address at 2225 Colorado Avenue, Santa Monica, California 90404 (“Kite”). Kite and Amgen are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.